Which agents should we use for the treatment of multidrug-resistant Mycobacterium tuberculosis?
about
Recent advances in the Suf Fe-S cluster biogenesis pathway: Beyond the ProteobacteriaInhibition of the PLP-dependent enzyme serine palmitoyltransferase by cycloserine: evidence for a novel decarboxylative mechanism of inactivationSynthesis and structural activity relationship study of antitubercular carboxamidesSulfur mobilization for Fe-S cluster assembly by the essential SUF pathway in the Plasmodium falciparum apicoplast and its inhibitionIsoniazid inhibits the heme-based reactivity of Mycobacterium tuberculosis truncated hemoglobin NIs antibiotic resistance a problem? A practical guide for hospital clinicians.Rapid detection of rpoB mutations in rifampin resistant M. tuberculosis from sputum samples by denaturing gradient gel electrophoresisUnderstanding drug ototoxicity: molecular insights for prevention and clinical management.Bacteriophage and their lysins for elimination of infectious bacteria.Antituberculosis drugs: drug interactions, adverse effects, and use in special situations. Part 2: second line drugs.Recent advances in the design and synthesis of heterocycles as anti-tubercular agents.The chemistry and biology of organic guanidine derivatives.Endocrine and metabolic abnormalities among HIV-infected patients: a current review.Genetic and phenotypic characterization of drug-resistant Mycobacterium tuberculosis isolates in Hong Kong.D-cycloserine or similar physiochemical compounds may be uniquely suited for use in Bacillus anthracis spore decontamination strategies.Systematic evaluation of structure-activity relationships of the riminophenazine class and discovery of a C2 pyridylamino series for the treatment of multidrug-resistant tuberculosis.Use of hydrogen peroxide vapor for deactivation of Mycobacterium tuberculosis in a biological safety cabinet and a room.Iron-sulfur clusters biogenesis by the SUF machinery: close to the molecular mechanism understanding.Differences in VigiBase® reporting of aminoglycoside and capreomycin-suspected ototoxicity during tuberculosis treatment.Pharmacokinetics of rifampicin in Mexican patients with tuberculosis and healthy volunteers.Mutation EthAW21R confers co-resistance to prothionamide and ethionamide in both Mycobacterium bovis BCG and Mycobacterium tuberculosis H37Rv.Relapse Versus Reinfection of Recurrent Tuberculosis Patients in a National Tuberculosis Specialized Hospital in Beijing, China
P2860
Q27001189-7C8410A2-706E-4A50-AD1F-E6A5C1A48D22Q27661380-DC062E4B-0646-49E1-81D2-9EE09675D637Q28084238-13277A86-44DD-4621-8595-FDE030174B98Q30039224-26D93F6B-5448-42C1-9490-28A9D5C5BEEBQ34924586-08964C51-C472-444C-852C-F7A0CB77B294Q35523222-FBB4FAA8-DA79-4F54-B939-9F7D3DAC8C51Q35673513-BF9ABBF5-0F5E-45D3-889F-6C7A259C7092Q36446895-CC31B1FF-19EC-44A9-A72B-F639BEFD1345Q37470848-68D78AE4-35EE-42D5-B2F5-D12F1433E401Q37810481-3C7C72C5-64BD-4FD7-B173-01097833F5D4Q37855895-1ABA881B-5415-45ED-81AB-7DCFD486F81EQ38044691-0B8886C2-A63E-4779-8F56-2F2CBB228439Q38130907-679E9987-BA36-4445-A090-11F56C38E5EFQ42182714-3311B6EF-3B79-49DD-9F1C-B27FE4F67156Q42251905-04E565B4-7455-496C-8F77-21B45CC28062Q42718752-CFA51BB2-D4B0-40F4-AE68-BA8A8E158071Q42912322-CAF8F963-736C-4946-9235-D4D14AFF0438Q47177647-3D5C3EC0-BDF7-4161-8FBB-47FEC505482DQ50315312-37FF9F26-3871-4EFC-8535-7330ACDE61D6Q51139486-4CAA803B-FA64-4FBB-B057-9B828AA9E3C7Q55361113-62C075CC-BC23-49B7-A74F-1CB6250AE487Q58781770-4625CA51-FACE-4F3E-A465-492124DDF192
P2860
Which agents should we use for the treatment of multidrug-resistant Mycobacterium tuberculosis?
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Which agents should we use for ...... nt Mycobacterium tuberculosis?
@ast
Which agents should we use for ...... nt Mycobacterium tuberculosis?
@en
type
label
Which agents should we use for ...... nt Mycobacterium tuberculosis?
@ast
Which agents should we use for ...... nt Mycobacterium tuberculosis?
@en
prefLabel
Which agents should we use for ...... nt Mycobacterium tuberculosis?
@ast
Which agents should we use for ...... nt Mycobacterium tuberculosis?
@en
P2860
P356
P1476
Which agents should we use for ...... nt Mycobacterium tuberculosis?
@en
P2093
Giovanni Di Perri
Stefano Bonora
P2860
P304
P356
10.1093/JAC/DKH377
P407
P577
2004-07-28T00:00:00Z